Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Feng YuXiaoyan WangHui ShiMaorong JiangJun XuMin SunQinggang XuFrank Peprah AddaiHaifeng ShiJie GuYang ZhouLiqiong LiuPublished in: Tumori (2020)
An effective HER2 CAR targeting ESCC was developed successfully. The HER2.CAR-T cell showed promising immunotherapeutic potential for the treatment of HER2-positive esophageal cancer.
Keyphrases